195 related articles for article (PubMed ID: 33336447)
1. Alcohol intake potentiates clozapine adverse effects associated to CYP1A2*1C in patients with refractory psychosis.
Ortega-Vázquez A; Mayen-Lobo YG; Dávila-Ortiz de Montellano DJ; Tristán-López L; Aviña-Cervantes CL; Ríos C; López-López M; Monroy-Jaramillo N
Drug Dev Res; 2021 Aug; 82(5):685-694. PubMed ID: 33336447
[TBL] [Abstract][Full Text] [Related]
2. The role of alcohol intake in the pharmacogenetics of treatment with clozapine.
Monroy-Jaramillo N; Martínez-Magaña JJ; Pérez-Aldana BE; Ortega-Vázquez A; Montalvo-Ortiz J; López-López M
Pharmacogenomics; 2022 Apr; 23(6):371-392. PubMed ID: 35311547
[TBL] [Abstract][Full Text] [Related]
3. Clinical and genetic influencing factors on clozapine pharmacokinetics in Tunisian schizophrenic patients.
Ammar H; Chadli Z; Mhalla A; Khouadja S; Hannachi I; Alshaikheid M; Slama A; Ben Fredj N; Ben Fadhel N; Ben Romdhane H; Chaabane A; Boughattas NA; Gaha L; Zarrouk L; Aouam K
Pharmacogenomics J; 2021 Oct; 21(5):551-558. PubMed ID: 33731885
[TBL] [Abstract][Full Text] [Related]
4. The Potential Role of
Demirbugen Oz M; Ozdemir F; Tok KC; Dural E; Kir Y; Ulusoy M; Gumustas M; Baskak B; Suzen HS
Expert Opin Drug Metab Toxicol; 2023; 19(5):319-327. PubMed ID: 37269349
[TBL] [Abstract][Full Text] [Related]
5. Effects of caffeine withdrawal from the diet on the metabolism of clozapine in schizophrenic patients.
Carrillo JA; Herraiz AG; Ramos SI; Benítez J
J Clin Psychopharmacol; 1998 Aug; 18(4):311-6. PubMed ID: 9690697
[TBL] [Abstract][Full Text] [Related]
6. Association between CYP1A2 polymorphisms and clozapine-induced adverse reactions in patients with schizophrenia.
Ferrari M; Bolla E; Bortolaso P; Callegari C; Poloni N; Lecchini S; Vender S; Marino F; Cosentino M
Psychiatry Res; 2012 Dec; 200(2-3):1014-7. PubMed ID: 22901441
[TBL] [Abstract][Full Text] [Related]
7. Effect of lemborexant on pharmacokinetics of clozapine: A potential drug-drug interaction mediated by time-dependent inhibition of CYP3A4.
Watanabe K; Misaka S; Kanno-Nozaki K; Chiyoda T; Suzuki Y; Sato A; Suto T; Kuroda J; Shimomura K; Miura I; Yabe H
Br J Clin Pharmacol; 2024 Jan; 90(1):354-359. PubMed ID: 37596710
[TBL] [Abstract][Full Text] [Related]
8. Variation in the Response of Clozapine Biotransformation Pathways in Human Hepatic Microsomes to CYP1A2- and CYP3A4-selective Inhibitors.
Murray M; Zhang WV; Edwards RJ
Basic Clin Pharmacol Toxicol; 2018 Apr; 122(4):388-395. PubMed ID: 29155491
[TBL] [Abstract][Full Text] [Related]
9. The involvement of CYP1A2 and CYP3A4 in the metabolism of clozapine.
Eiermann B; Engel G; Johansson I; Zanger UM; Bertilsson L
Br J Clin Pharmacol; 1997 Nov; 44(5):439-46. PubMed ID: 9384460
[TBL] [Abstract][Full Text] [Related]
10. Genetic Determinants of Clozapine-Induced Metabolic Side Effects.
Vasudev K; Choi YH; Norman R; Kim RB; Schwarz UI
Can J Psychiatry; 2017 Feb; 62(2):138-149. PubMed ID: 27681143
[TBL] [Abstract][Full Text] [Related]
11. Exploring clozapine pharmacokinetics in Tunisian schizophrenic patients: A population-based modelling approach investigating the impact of genetic and non-genetic variables.
Mansour K; Fredj NB; Ammar H; Romdhane HB; Mhalla A; Chaabane A; Chadli Z; Aouam K
Basic Clin Pharmacol Toxicol; 2024 Jun; 134(6):805-817. PubMed ID: 38599832
[TBL] [Abstract][Full Text] [Related]
12. A pharmacogenetic intervention for the improvement of the safety profile of antipsychotic treatments.
Arranz MJ; Gonzalez-Rodriguez A; Perez-Blanco J; Penadés R; Gutierrez B; Ibañez L; Arias B; Brunet M; Cervilla J; Salazar J; Catalan R
Transl Psychiatry; 2019 Jul; 9(1):177. PubMed ID: 31346157
[TBL] [Abstract][Full Text] [Related]
13. Impact of CYP1A2 and CYP2D6 polymorphisms on drug metabolism and on insulin and lipid elevations and insulin resistance in clozapine-treated patients.
Melkersson KI; Scordo MG; Gunes A; Dahl ML
J Clin Psychiatry; 2007 May; 68(5):697-704. PubMed ID: 17503978
[TBL] [Abstract][Full Text] [Related]
14. Pharmacogenetics of clozapine treatment response and side-effects in schizophrenia: an update.
Sriretnakumar V; Huang E; Müller DJ
Expert Opin Drug Metab Toxicol; 2015; 11(11):1709-31. PubMed ID: 26364648
[TBL] [Abstract][Full Text] [Related]
15. Exploring the usefulness of plasma level determination and pharmacogenetics for patients treated with clozapine.
Sangüesa E; Cirujeda C; Concha J; Padilla PP; García CB; Ribate MP
Per Med; 2022 May; 19(3):181-192. PubMed ID: 35259926
[TBL] [Abstract][Full Text] [Related]
16. Increased clozapine plasma concentrations and side effects induced by smoking cessation in 2 CYP1A2 genotyped patients.
Bondolfi G; Morel F; Crettol S; Rachid F; Baumann P; Eap CB
Ther Drug Monit; 2005 Aug; 27(4):539-43. PubMed ID: 16044115
[TBL] [Abstract][Full Text] [Related]
17. The CYP1A2 -163C>A polymorphism is associated with clozapine-induced generalized tonic-clonic seizures in Brazilian schizophrenia patients.
Kohlrausch FB; Severino-Gama C; Lobato MI; Belmonte-de-Abreu P; Carracedo A; Hutz MH
Psychiatry Res; 2013 Sep; 209(2):242-5. PubMed ID: 23601795
[TBL] [Abstract][Full Text] [Related]
18. CYP1A2 polymorphism -1545C > T (rs2470890) is associated with increased side effects to clozapine.
Viikki M; Kampman O; Seppälä N; Mononen N; Lehtimäki T; Leinonen E
BMC Psychiatry; 2014 Feb; 14():50. PubMed ID: 24555493
[TBL] [Abstract][Full Text] [Related]
19. Impact of CYP1A2, CYP2C19, and CYP2D6 genotype- and phenoconversion-predicted enzyme activity on clozapine exposure and symptom severity.
Lesche D; Mostafa S; Everall I; Pantelis C; Bousman CA
Pharmacogenomics J; 2020 Apr; 20(2):192-201. PubMed ID: 31616047
[TBL] [Abstract][Full Text] [Related]
20. Characterization of the human hepatic cytochromes P450 involved in the in vitro oxidation of clozapine.
Tugnait M; Hawes EM; McKay G; Eichelbaum M; Midha KK
Chem Biol Interact; 1999 Apr; 118(2):171-89. PubMed ID: 10359460
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]